RAPT Therapeutics, Inc.

103 articles about RAPT Therapeutics, Inc.

• RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

  3/29/2023

  RAPT Therapeutics, Inc. today announced that it has initiated its global 14-week randomized, double-blind, placebo-controlled Phase 2a clinical trial to evaluate the efficacy and safety of RPT193.

• RAPT Therapeutics Reports Fourth Quarter And Year End Financial ResultsCompany maintains strong cash position of $249.1 million

  3/14/2023

  RAPT Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2022.

• RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

  2/7/2023

  RAPT Therapeutics, Inc. today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 1:40 p.m. Eastern Time.

• RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  RAPT Therapeutics, Inc. announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:00 p.m. Pacific Time.

• RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

  12/8/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT) today reported a poster presentation at the ESMO IO Congress covering data from its ongoing Phase 1/2 clinical trial of FLX475 as monotherapy and in combination with pembrolizumab in patients with advanced cancer (NCT03674567).

• RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

  11/30/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) today announced that its abstract from its ongoing Phase 1/2 study of FLX475 as monotherapy and in combination with pembrolizumab in cancer patients has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress taking place December 7-9, 2022 in Geneva, Switzerland.

• RAPT Therapeutics Announces Pricing of Public Offering of Common Stock - November 18, 2022

  11/18/2022

  RAPT Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of 4,054,055 shares of its common stock at a price to the public of $18.50 per share.

• RAPT Therapeutics Announces Proposed Public Offering of Common Stock - November 17, 2022

  11/17/2022

  RAPT Therapeutics, Inc. announced that it has commenced an underwritten public offering of $75 million of its common stock.

• RAPT Therapeutics Reports Third Quarter 2022 Financial Results

  11/10/2022

  RAPT Therapeutics, Inc. today reported financial results for the quarter and nine months ended September 30, 2022.

• RAPT Therapeutics to Participate in Several Upcoming Investor Conferences

  11/9/2022

  RAPT Therapeutics, Inc. today announced that members of the RAPT management team will participate in the following investor conferences in November.

• RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

  8/31/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September.

• RAPT Therapeutics Reports Second Quarter 2022 Financial ResultsCompany maintains strong cash position of $207.3 million

  8/11/2022

  RAPT Therapeutics, Inc. today reported financial results for the quarter and six months ended June 30, 2022.

• RAPT Therapeutics Announces Private Placement Financing of $50 Million

  5/25/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced a $50 million private investment in public equity (PIPE) financing from the sale of pre-funded warrants.

• RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis

  5/23/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).

• RAPT Therapeutics Reports First Quarter 2022 Financial Results

  5/11/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the quarter ended March 31, 2022.

• RAPT Therapeutics Expands Leadership Team with Multiple Key Hires

  5/4/2022

  RAPT Therapeutics, Inc. today announced the appointments of Gwen Carscadden as Chief Human Resources Officer, Jim Farmer as Vice President of Clinical Operations and Shari Geffon as Vice President of Program and Alliance Management.

• RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis

  3/28/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced biomarker data from the company’s randomized placebo-controlled Phase 1b clinical trial of RPT193 in patients with moderate-to-severe atopic dermatitis (AD) were consistent with previously reported top-line data which showed clear improvement in key exploratory efficacy measures.

• RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results

  3/10/2022

  RAPT Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2021.

• RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference

  2/9/2022

  RAPT Therapeutics, Inc. announced that Brian Wong, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at the 11th Annual SVB Leerink Healthcare Conference on Wednesday, February 16, 2022 at 1:40 p.m. ET.

• RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:00 a.m. ET.